Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(73)
•••
Comment by Captainblkon Jan 08, 2020 4:38pm
121 Views
Post# 30532168

RE:Possible partner only an educated guess

RE:Possible partner only an educated guess
MyKnight wrote: Does are the top company on the world dealing with GVHD, they will loose this market if they don't have an agreement with Kaly...

As I was talking to rob this summer, he  set at a minimum price of 5 Billions, I though that was agressive ...  I don't anymore once we look at which company we're dealing with, and the market that kaly will take from them...

This is only speculation from my part but I belive that they have the licence set up with one of does, and after they had a chance of trying it out in Europe, they would buy them at the Price that Rob ask ... 

And you can see that buying kaly at 5 Billions would be easy and a great deal for them...

Bristol-Myers Squibb (161 Billions Market Cap)
Abbott (155 Billions MC)
AbbVie (132 Billions)
Allergan (63 Billions)
Anterogen(334 Billions)
Astellas Pharma (3 450 Billions)
Athersys (189 Billions)
Eli Lilly (127 Billions)
GlaxoSmithKline (89 Billions)
Glenmark (96 Billions)
Sanofi (115 Billions)
Shire(54 Billions)

Soon ....


pardon my napkin math, as I haven't had enough coffee. but wouldnt that put the SP in the realm of $9?
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities